FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2008
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

KOLTERMAN ORVILLE G 		2. Issuer Name and Ticker or Trading Symbol

AMYLIN PHARMACEUTICALS INC [ AMLN ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Sr VP Clinical and Regulatory
(Last)          (First)          (Middle)

9360 TOWNE CENTRE DR 		3. Date of Earliest Transaction (MM/DD/YYYY)

3/10/2008
(Street)

SAN DIEGO, CA 92121
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   3/10/2008     M    4344   A $3.281   124957   (1) D    
Common Stock   3/10/2008     M    1096   A $2.906   126053   D    
Common Stock   3/10/2008     M    163   A $3.281   126216   D    
Common Stock   3/10/2008     M    5   A $0.313   126221   D    
Common Stock                  905   I   by ESOP   (2)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Incentive Stock Option (right to buy)   $0.313   3/10/2008     M        5      (3) 10/23/2008   Common Stock   5   $0   0   D    
Incentive Stock Option (right to buy)   $3.281   3/10/2008     M        163      (4) 4/9/2008   Common Stock   163   $0   0   D    
Non-Qualified Stock Option (right to buy)   $2.906   3/10/2008     M        1096      (5) 3/13/2008   Common Stock   1096   $0   0   D    
Non-Qualified Stock Option (right to buy)   $3.281   3/10/2008     M        4344      (4) 4/9/2008   Common Stock   4344   $0   0   D    

Explanation of Responses:
( 1)  Includes 444 shares acquired on February 29,2008 under the company's employee stock purchase plan.
( 2)  Reflects ESOP allocations that have occurred since the date of the reporting person's last ownership report. These shares fully vest four years from the date of the reporting person's participation in the ESOP in four equal annual installments and are generally distributed upon termination of employment.
( 3)  25,000 options vested on 10/23/1999, and daily after that, until all the 100,000 options were completely vested on 10/23/2002.
( 4)  15,000 options vested on 06/30/1999, 2,723 options vested on 12/31/1999 and daily after that, until the options were completely vested on 04/09/2002.
( 5)  5,175 options vested on 03/13/99, and daily after that, until all the 20,700 options were completely vested on 03/13/2002.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
KOLTERMAN ORVILLE G
9360 TOWNE CENTRE DR
SAN DIEGO, CA 92121

Sr VP Clinical and Regulatory

Signatures
By: /s/James R. Oehler, Attorney-in-Fact For: Orville G. Kolterman 3/11/2008
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Amylin Pharmaceuticals, Inc. (MM) Charts.
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Amylin Pharmaceuticals, Inc. (MM) Charts.